Speculation Sickens the Dow, Pharma Tries to Cure It
Pure speculation has sent the market into losing territory. But the big pharma pack may have just the right medicine for the Dow.
A Closer Look at GlaxoSmithKline's Dividend Potential
Is GlaxoSmithKline a solid pick for dividend growth?
Some Fish Oil Doesn't Help Some Patients in Some Countries
Be careful reading too much into the recently published clinical trial.
Why Theravance Shareholders Can Breathe Easier
A long-awaited FDA drug approval sends shares roaring higher.